CLINICAL_TRIALS ClinicalTrials.gov record update

Recurrent Brain Metastasis Immune Effects and RespOnse to Laser Interstitial ThermotHerapy (LITT) and Pembrolizumab in Combination (TORCH)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04187872
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:24.028652+00:00
Published At: 2023-12-27T00:00:00+00:00
Record Updated At: 2023-12-27
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Melanoma", "Non-small Cell Lung Carcinoma (NSCLC)", "Renal Cell Carcinoma (RCC)", "Small-cell Lung Cancer", "Head and Neck Squamous Cell Cancer", "Classical Hodgkin Lymphoma", "Primary Mediastinal Large B-Cell Lymphoma", "Urothelial Carcinoma", "Microsatellite Instability-High Cancer", "Gastric Cancer", "Esophageal Cancer", "Cervical Cancer", "Hepatocellular Carcinoma", "Merkel Cell Carcinoma", "Brain Metastases, Adult"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-12-27"
protocolSection.identificationModule.nctId: "NCT04187872"
protocolSection.identificationModule.officialTitle: "Recurrent Brain Metastasis Immune Effects and RespOnse to Laser Interstitial ThermotHerapy (LITT) and Pembrolizumab in Combination (TORCH)"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.